Which diabetes drug fights fatty liver better? new study pits dapagliflozin against empagliflozin
NCT ID NCT07363707
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed phase 4 trial compared two common diabetes drugs, dapagliflozin and empagliflozin, added to metformin in 108 adults with type 2 diabetes and nonalcoholic fatty liver disease (NAFLD). Participants took one of the two drugs daily for six months. Researchers used liver scans and blood tests to measure changes in liver fat and function, aiming to see which drug works better for NAFLD.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
dapagliflozin and empagliflozin (SGLT2 inhibitors)
What this could lead to
If successful, this study could show which SGLT2 inhibitor is better at reducing liver fat in people with type 2 diabetes and NAFLD, potentially guiding treatment choices.
What could go wrong
This is a small, completed phase 4 trial with only 108 participants, so results may not apply to everyone. The primary outcomes are surrogate markers (liver stiffness and blood tests), not hard endpoints like liver-related illness or death.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES MELLITUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beni Suef University Hospital
Cairo, Egypt